Test Code MDS2 Movement Disorder, Autoimmune/Paraneoplastic Evaluation, Serum
Reporting Name
Movement, Autoimm/Paraneo, SPerforming Laboratory
Mayo Clinic Laboratories in RochesterUseful For
Evaluating patients with suspected paraneoplastic or other autoimmune movement disorders including patients with ataxia, brainstem encephalitis, chorea, dyskinesias, myoclonus, and parkinsonism using serum specimens
Method Name
GRFIS, GRFTS, K11TS, AGN1S, AGNTS, AMPIS, AMPHS, APHTS, ANN1S, AN1TS, ANN2S, AN2TS, ANN3S, AN3TS, APBIS, APBTS, CRMTS, DPPTS, GABIS, GFAIS, GFATS, IG5TS, ITPIS, ITPTS, GL1IS, GL1TS, NCDIS, NCDTS, NIFIS, NIFTS, NMDIS, PCABP, PC1TS, PCAB2, PC2TS, PCATR, PCTTS, PDEIS, PDETS, SP7IS, SP7TS, SP5IS, SP5TS, T46IS, T46TS: Indirect Immunofluorescence Assay (IFA)
GRFCS, K11CS, AMPCS, APBCS, CS2CS, DPPCS, GABCS, GFACS, IG5CS, ITPCS, LG1CS, GL1CS, NCDCS, AINCS, NFLCS, NFHCS, NMDCS, SP7CS, SP5CS, T46CS: Cell Binding Assay (CBA)
CRMWS: Western Blot (WB)
AGNBS, AMIBS, AN1BS, AN2BS, PC1BS, PCTBS: Immunoblot (IB)
CCPQ, GD65S: Radioimmunoassay (RIA)
MDSI: Medical interpretation
Ordering Guidance
Multiple neurological phenotype-specific autoimmune/paraneoplastic evaluations are available. For more information as well as phenotype-specific testing options, refer to Autoimmune Neurology Test Ordering Guide.
When more than one evaluation is ordered on the same order number the duplicate will be canceled.
For a list of antibodies performed with each evaluation, see Autoimmune Neurology Antibody Matrix.
This test should not be requested for patients who have recently received radioisotopes, therapeutically or diagnostically, because of potential assay interference. The specific waiting period before specimen collection will depend on the isotope administered, the dose given, and the clearance rate in the individual patient. Specimens will be screened for radioactivity prior to analysis. Radioactive specimens received in the laboratory will be held 1 week and assayed if sufficiently decayed or canceled if radioactivity remains.
Necessary Information
Provide the following information:
-Relevant clinical information
-Ordering provider name, phone number, mailing address, and e-mail address
Specimen Required
Patient Preparation: For optimal antibody detection, specimen collection is recommended before initiation of immunosuppressant medication or intravenous immunoglobulin treatment.
Supplies: Sarstedt Aliquot Tube 5 mL (T914)
Collection Container/Tube:
Preferred: Red top
Acceptable: Serum gel
Submission Container/Tube: Plastic vial
Specimen Volume: 4 mL
Collection Instructions: Centrifuge and aliquot serum into a plastic vial.
Specimen Type
SerumSpecimen Minimum Volume
3 mL
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Serum | Refrigerated (preferred) | 28 days | |
Frozen | 28 days | ||
Ambient | 72 hours |
Reject Due To
Gross hemolysis | Reject |
Gross lipemia | Reject |
Gross icterus | Reject |
Reference Values
Test ID |
Reporting Name |
Methodology* |
Reference Value |
MDSI |
Movement Disorder Interp, S |
Medical interpretation |
Interpretive report |
AMPCS |
AMPA-R Ab CBA, S |
CBA |
Negative |
AMPHS |
Amphiphysin Ab, S |
IFA |
Negative |
AGN1S |
Anti-Glial Nuclear Ab, Type 1 |
IFA |
Negative |
ANN1S |
Anti-Neuronal Nuclear Ab, Type 1 |
IFA |
Negative |
ANN2S |
Anti-Neuronal Nuclear Ab, Type 2 |
IFA |
Negative |
ANN3S |
Anti-Neuronal Nuclear Ab, Type 3 |
IFA |
Negative |
APBIS |
AP3B2 IFA, S |
IFA |
Negative |
CS2CS |
CASPR2-IgG CBA, S |
CBA |
Negative |
CRMWS |
CRMP-5-IgG Western Blot, S |
WB |
Negative |
DPPCS |
DPPX Ab CBA, S |
CBA |
Negative |
GABCS |
GABA-B-R Ab CBA, S |
CBA |
Negative |
GD65S |
GAD65 Ab Assay, S |
RIA |
≤0.02 nmol/L Reference values apply to all ages. |
GFAIS |
GFAP IFA, S |
IFA |
Negative |
GRFIS |
GRAF1 IFA, S |
IFA |
Negative |
IG5CS |
IgLON5 CBA, S |
CBA |
Negative |
ITPIS |
ITPR1 IFA, S |
IFA |
Negative |
K11CS |
KLHL11 Ab CBA, S |
CBA |
Negative |
LG1CS |
LGI1-IgG CBA, S |
CBA |
Negative |
GL1IS |
mGluR1 Ab IFA, S |
IFA |
Negative |
NCDIS |
Neurochondrin IFA, S |
IFA |
Negative |
NIFIS |
NIF IFA, S |
IFA |
Negative |
NMDCS |
NMDA-R Ab CBA, S |
CBA |
Negative |
CCPQ |
P/Q-Type Calcium Channel Ab |
RIA |
≤0.02 nmol/L |
PCABP |
Purkinje Cell Cytoplasmic Ab Type 1 |
IFA |
Negative |
PCAB2 |
Purkinje Cell Cytoplasmic Ab Type 2 |
IFA |
Negative |
PCATR |
Purkinje Cell Cytoplasmic Ab Type Tr |
IFA |
Negative |
PDEIS |
PDE10A Ab IFA, S |
IFA |
Negative |
SP5IS |
Septin-5 IFA, S |
IFA |
Negative |
SP7IS |
Septin-7 IFA, S |
IFA |
Negative |
T46IS |
TRIM46 Ab IFA, S |
IFA |
Negative |
Reflex Information:
Test ID |
Reporting Name |
Methodology* |
Reference Value |
AGNBS |
AGNA-1 Immunoblot, S |
IB |
Negative |
AGNTS |
AGNA-1 Titer, S |
IFA |
<1:240 |
AINCS |
Alpha Internexin CBA, S |
CBA |
Negative |
AMPIS |
AMPA-R Ab IF Titer Assay, S |
IFA |
<1:240 |
AMIBS |
Amphiphysin Immunoblot, S |
IB |
Negative |
AN1BS |
ANNA-1 Immunoblot, S |
IB |
Negative |
AN1TS |
ANNA-1 Titer, S |
IFA |
<1:240 |
AN2BS |
ANNA-2 Immunoblot, S |
IB |
Negative |
AN2TS |
ANNA-2 Titer, S |
IFA |
<1:240 |
AN3TS |
ANNA-3 Titer, S |
IFA |
<1:240 |
APBCS |
AP3B2 CBA, S |
CBA |
Negative |
APBTS |
AP3B2 IFA Titer, S |
IFA |
<1:240 |
APHTS |
Amphiphysin Ab Titer, S |
IFA |
<1:240 |
CRMTS |
CRMP-5-IgG Titer, S |
IFA |
<1:240 |
DPPTS |
DPPX Ab IFA Titer, S |
IFA |
<1:240 |
GABIS |
GABA-B-R Ab IF Titer Assay, S |
IFA |
<1:240 |
GFACS |
GFAP CBA, S |
CBA |
Negative |
GFATS |
GFAP IFA Titer, S |
IFA |
<1:240 |
GRFCS |
GRAF1 CBA, S |
CBA |
Negative |
GRFTS |
GRAF1 IFA Titer, S |
IFA |
<1:240 |
IG5TS |
IgLON5 IFA Titer, S |
IFA |
<1:240 |
ITPCS |
ITPR1 CBA, S |
CBA |
Negative |
ITPTS |
ITPR1 IFA Titer, S |
IFA |
<1:240 |
K11TS |
KLHL11 Ab IFA Titer, S |
IFA |
<1:240 |
GL1CS |
mGluR1 Ab CBA, S |
CBA |
Negative |
GL1TS |
mGluR1 Ab IFA Titer, S |
IFA |
<1:240 |
NCDCS |
Neurochondrin CBA, S |
CBA |
Negative |
NCDTS |
Neurochondrin IFA Titer, S |
IFA |
<1:240 |
NFHCS |
NIF Heavy Chain CBA, S |
CBA |
Negative |
NIFTS |
NIF IFA Titer, S |
IFA |
<1:240 |
NFLCS |
NIF Light Chain CBA, S |
CBA |
Negative |
NMDIS |
NMDA-R Ab IF Titer Assay, S |
IFA |
<1:240 |
PC1BS |
PCA-1 Immunoblot, S |
IB |
Negative |
PC1TS |
PCA-1 Titer, S |
IFA |
<1:240 |
PC2TS |
PCA-2 Titer, S |
IFA |
<1:240 |
PCTBS |
PCA-Tr Immunoblot, S |
IB |
Negative |
PCTTS |
PCA-Tr Titer, S |
IFA |
<1:240 |
PDETS |
PDE10A Ab IFA Titer, S |
IFA |
<1:240 |
SP5CS |
Septin-5 CBA, S |
CBA |
Negative |
SP5TS |
Septin-5 IFA Titer, S |
IFA |
<1:240 |
SP7CS |
Septin-7 CBA, S |
CBA |
Negative |
SP7TS |
Septin-7 IFA Titer, S |
IFA |
<1:240 |
T46CS |
TRIM46 Ab CBA, S |
CBA |
Negative |
T46TS |
TRIM46 Ab IFA Titer, S |
IFA |
<1:240 |
*Methodology abbreviations:
Immunofluorescence assay (IFA)
Cell-binding assay (CBA)
Western blot (WB)
Radioimmunoassay (RIA)
Immunoblot (IB)
Neuron-restricted patterns of IgG staining that do not fulfill criteria for ANNA-1, ANNA-2, ANNA-3, CRMP-5-IgG, PCA-1, PCA-2, or PCA-Tr may be reported as "unclassified anti-neuronal IgG." Complex patterns that include nonneuronal elements may be reported as "uninterpretable."
Interpretation
A positive antibody result is consistent with a diagnosis of an autoimmune movement disorder.
A search for cancer may be indicated, depending on the antibody profile.
A trial of immune therapy may bring about improvement in neurological symptoms.
Day(s) Performed
Profile tests: Monday through Sunday; Reflex tests: Varies
Report Available
8 to 12 daysTest Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
86596
86255 x 26
84182
86341
0432U
84182 AGNBS (if appropriate)
86256 AGNTS (if appropriate)
86255 AINCS (if appropriate)
84182 AMIBS (if appropriate)
86256 AMPIS (if appropriate)
84182 AN1BS (if appropriate)
86256 AN1TS (if appropriate)
84182 AN2BS (if appropriate)
86256 AN2TS (if appropriate)
86256 AN3TS (if appropriate)
86255 APBCS (if appropriate)
86256 APBTS (if appropriate)
86256 APHTS (if appropriate)
86256 CRMTS (if appropriate)
86256 DPPTS (if appropriate)
86256 GABIS (if appropriate)
86255 GFACS (if appropriate)
86256 GFATS (if appropriate)
86255 GL1CS (if appropriate)
86256 GL1TS (if appropriate)
86255 GRFCS (if appropriate)
86256 GRFTS (if appropriate)
86256 IG5TS (if appropriate)
86255 ITPCS (if appropriate)
86256 ITPTS (if appropriate)
86256 K11TS (if appropriate)
86255 NCDCS (if appropriate)
86256 NCDTS (if appropriate)
86255 NFHCS (if appropriate)
86255 NFLCS (if appropriate)
86256 NIFTS (if appropriate)
86256 NMDIS (if appropriate)
84182 PC1BS (if appropriate)
86256 PC1TS (if appropriate)
86256 PC2TS (if appropriate)
84182 PCTBS (if appropriate)
86256 PCTTS (if appropriate)
86256 PDETS (if appropriate)
86255 SP5CS (if appropriate)
86256 SP5TS (if appropriate)
86255 SP7CS (if appropriate)
86256 SP7TS (if appropriate)
86255 T46CS (if appropriate)
86256 T46TS (if appropriate)
LOINC Code Information
Test ID | Test Order Name | Order LOINC Value |
---|---|---|
MDS2 | Movement, Autoimm/Paraneo, S | 94701-0 |
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
61516 | NMDA-R Ab CBA, S | 93503-1 |
61518 | AMPA-R Ab CBA, S | 93489-3 |
61519 | GABA-B-R Ab CBA, S | 93428-1 |
606950 | IgLON5 CBA, S | 96478-3 |
610581 | KLHL11 Ab CBA, S | 99072-1 |
615867 | Neurochondrin IFA, S | 101452-1 |
615871 | Septin-5 IFA, S | 101460-4 |
615875 | Septin-7 IFA, S | 101465-3 |
615863 | AP3B2 IFA, S | 101907-4 |
616445 | TRIM46 Ab IFA, S | 103843-9 |
620068 | PDE10A Ab IFA, S | 103842-1 |
605155 | GFAP IFA, S | 94346-4 |
606952 | ITPR1 IFA, S | 96464-3 |
606964 | NIF IFA, S | 96486-6 |
606958 | GRAF1 IFA, S | 96471-8 |
64279 | LGI1-IgG CBA, S | 94287-0 |
64281 | CASPR2-IgG CBA, S | 94285-4 |
64933 | DPPX Ab CBA, S | 94676-4 |
64928 | mGluR1 Ab IFA, S | 94347-2 |
601998 | Movement Disorder Interp, S | 69048-7 |
89080 | AGNA-1, S | 84927-3 |
81722 | Amphiphysin Ab, S | 72327-0 |
80150 | ANNA-1, S | 33615-6 |
80776 | ANNA-2, S | 43187-4 |
83137 | ANNA-3, S | 43102-3 |
81185 | P/Q-Type Calcium Channel Ab | 94349-8 |
83107 | CRMP-5-IgG Western Blot, S | 47401-5 |
81596 | GAD65 Ab Assay, S | 30347-9 |
83138 | PCA-2, S | 84925-7 |
9477 | PCA-1, S | 84924-0 |
83076 | PCA-Tr, S | 84926-5 |
618903 | IFA Notes | 48767-8 |
Forms
If not ordering electronically, complete, print, and send a Neurology Specialty Testing Client Test Request (T732) with the specimen.
Profile Information
Test ID | Reporting Name | Available Separately | Always Performed |
---|---|---|---|
MDSI | Movement Disorder Interp, S | No | Yes |
AMPCS | AMPA-R Ab CBA, S | No | Yes |
AMPHS | Amphiphysin Ab, S | No | Yes |
AGN1S | Anti-Glial Nuclear Ab, Type 1 | No | Yes |
ANN1S | Anti-Neuronal Nuclear Ab, Type 1 | No | Yes |
ANN2S | Anti-Neuronal Nuclear Ab, Type 2 | No | Yes |
ANN3S | Anti-Neuronal Nuclear Ab, Type 3 | No | Yes |
APBIS | AP3B2 IFA, S | No | Yes |
CS2CS | CASPR2-IgG CBA, S | No | Yes |
CRMWS | CRMP-5-IgG Western Blot, S | Yes | Yes |
DPPCS | DPPX Ab CBA, S | No | Yes |
GABCS | GABA-B-R Ab CBA, S | No | Yes |
GD65S | GAD65 Ab Assay, S | Yes | Yes |
GFAIS | GFAP IFA, S | No | Yes |
GRFIS | GRAF1 IFA, S | No | Yes |
IG5CS | IgLON5 CBA, S | No | Yes |
ITPIS | ITPR1 IFA, S | No | Yes |
K11CS | KLHL11 Ab CBA, S | Yes | Yes |
LG1CS | LGI1-IgG CBA, S | No | Yes |
GL1IS | mGluR1 Ab IFA, S | No | Yes |
NCDIS | Neurochondrin IFA, S | No | Yes |
NIFIS | NIF IFA, S | No | Yes |
NMDCS | NMDA-R Ab CBA, S | No | Yes |
CCPQ | P/Q-Type Calcium Channel Ab | No | Yes |
PCABP | Purkinje Cell Cytoplasmic Ab Type 1 | No | Yes |
PCAB2 | Purkinje Cell Cytoplasmic Ab Type 2 | No | Yes |
PCATR | Purkinje Cell Cytoplasmic Ab Type Tr | No | Yes |
PDEIS | PDE10A Ab IFA, S | No | Yes |
SP5IS | Septin-5 IFA, S | No | Yes |
SP7IS | Septin-7 IFA, S | No | Yes |
T46IS | TRIM46 Ab IFA, S | No | Yes |
Reflex Tests
Test ID | Reporting Name | Available Separately | Always Performed |
---|---|---|---|
AGNBS | AGNA-1 Immunoblot, S | No | No |
AINCS | Alpha Internexin CBA, S | No | No |
AMPIS | AMPA-R Ab IF Titer Assay, S | No | No |
AMIBS | Amphiphysin Immunoblot, S | No | No |
AN1BS | ANNA-1 Immunoblot, S | No | No |
AN2BS | ANNA-2 Immunoblot, S | No | No |
DPPTS | DPPX Ab IFA Titer, S | No | No |
GABIS | GABA-B-R Ab IF Titer Assay, S | No | No |
GRFCS | GRAF1 CBA, S | No | No |
GRFTS | GRAF1 IFA Titer, S | No | No |
IG5TS | IgLON5 IFA Titer, S | No | No |
ITPCS | ITPR1 CBA, S | No | No |
ITPTS | ITPR1 IFA Titer, S | No | No |
GL1CS | mGluR1 Ab CBA, S | No | No |
GL1TS | mGluR1 Ab IFA Titer, S | No | No |
NFHCS | NIF Heavy Chain CBA, S | No | No |
NIFTS | NIF IFA Titer, S | No | No |
NFLCS | NIF Light Chain CBA, S | No | No |
NMDIS | NMDA-R Ab IF Titer Assay, S | No | No |
PC1BS | PCA-1 Immunoblot, S | No | No |
PCTBS | PCA-Tr Immunoblot, S | No | No |
K11TS | KLHL11 Ab IFA Titer, S | No | No |
AGNTS | AGNA-1 Titer, S | No | No |
AN1TS | ANNA-1 Titer, S | No | No |
AN2TS | ANNA-2 Titer, S | No | No |
AN3TS | ANNA-3 Titer, S | No | No |
APBCS | AP3B2 CBA, S | No | No |
APBTS | AP3B2 IFA Titer, S | No | No |
APHTS | Amphiphysin Ab Titer, S | No | No |
CRMTS | CRMP-5-IgG Titer, S | No | No |
GFACS | GFAP CBA, S | No | No |
GFATS | GFAP IFA Titer, S | No | No |
NCDCS | Neurochondrin CBA, S | No | No |
NCDTS | Neurochondrin IFA Titer, S | No | No |
PC1TS | PCA-1 Titer, S | No | No |
PC2TS | PCA-2 Titer, S | No | No |
PCTTS | PCA-Tr Titer, S | No | No |
SP5CS | Septin-5 CBA, S | No | No |
SP5TS | Septin-5 IFA Titer, S | No | No |
SP7CS | Septin-7 CBA, S | No | No |
SP7TS | Septin-7 IFA Titer, S | No | No |
PDETS | PDE10A Ab IFA Titer, S | No | No |
T46CS | TRIM46 Ab CBA, S | No | No |
T46TS | TRIM46 Ab IFA Titer, S | No | No |
Testing Algorithm
If the immunofluorescence assay (IFA) patterns suggest amphiphysin antibody, then the amphiphysin immunoblot and amphiphysin titer will be performed at an additional charge.
If the IFA pattern suggests antiglial nuclear antibody-1 (AGNA)-1, then the AGNA-1 immunoblot and AGNA-1 titer will be performed at an additional charge.
If the IFA pattern suggests antineuronal nuclear antibody type 1 (ANNA-1), then the ANNA-1 immunoblot, ANNA-1 titer, and ANNA-2 immunoblot will be performed at an additional charge.
If the IFA pattern suggests ANNA-2 antibody, then the ANNA-2 immunoblot, ANNA-2 titer, and ANNA-1 immunoblot will be performed at an additional charge.
If the client requests or the IFA pattern suggests ANNA-3 antibodies, then the ANNA-3 titer will be performed at an additional charge.
If the IFA pattern suggests adaptor protein 3 beta 2 (AP3B2) antibodies, then the AP3B2 cell-binding assay (CBA) and AP3B2 titer will be performed at an additional charge.
If the collapsin response-mediator protein-5 (CRMP-5)-IgG Western blot is positive, then the CRMP-5-IgG IFA titer will be performed at an additional charge.
If the IFA pattern suggests Purkinje cytoplasmic antibody type 1 (PCA-1), then the PCA-1 IB and PCA-1 titer will be performed at an additional charge.
If the IFA pattern suggests PCA-2 antibody, then the PCA-2 titer will be performed at an additional charge.
If the IFA pattern suggests PCA-Tr antibody, then the PCA-Tr IB and PCA-Tr titer will be performed at an additional charge.
If the IgLON5 antibody CBA result is positive, then IgLON5 antibody IFA titer will be performed at an additional charge.
If the IFA pattern suggests GTPase regulator associated with focal adhesion kinase-1 (GRAF1) antibody, then the GRAF1 CBA and GRAF1 antibody IFA titer will be performed at an additional charge.
If the IFA pattern suggests inositol 1,4,5-trisphosphate receptor (ITPR1) antibody, then the ITPR1 CBA and ITPR1 antibody IFA titer will be performed at an additional charge.
If the IFA pattern suggests alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA)-receptor antibody, then the AMPA-receptor antibody IFA titer will be performed at an additional charge.
If the dipeptidyl-peptidase-like protein-6 antibody (DPPX) antibody CBA result is positive, then the DPPX antibody IFA titer will be performed at an additional charge.
If the gamma-aminobutyric acid B (GABA-B)-receptor CBA result is positive, then the GABA-B-receptor antibody IFA titer will be performed at an additional charge.
If the IFA pattern suggests glial fibrillary acidic protein (GFAP) antibody, then the GFAP antibody CBA and GFAP antibody IFA titer will be performed at an additional charge.
If the IFA pattern suggests metabotropic glutamate receptor 1 (mGluR1) antibody, then the mGluR1 CBA and mGluR1 antibody IFA titer will be performed at an additional charge.
If the N-methyl-D-aspartate (NMDA)-receptor antibody CBA result is positive, then the NMDA-receptor antibody IFA titer is performed at an additional charge.
If the IFA pattern suggests neuronal intermediate filament (NIF) antibody, then the alpha internexin CBA, NIF heavy chain CBA, NIF light chain CBA, and NIF antibody IFA titer will be performed at an additional charge.
If the Kelch-like protein 11 (KLHL11) CBA result is reactive, then the KLHL11 antibody IFA titer will be performed at an additional charge.
If the IFA pattern suggests neurochondrin antibody, then the neurochondrin antibody CBA and neurochondrin titer will be performed at an additional charge.
If the IFA pattern suggests septin-5 antibody, then the septin-5 CBA and septin-5 titer will be performed at an additional charge.
If the IFA pattern suggests septin-7 antibody, then the septin-7 CBA and septin-7 titer are performed at an additional charge.
If the IFA pattern suggests tripartite motif-containing protein 46 (TRIM46) antibody, then the TRIM46 antibody CBA and TRIM46 IFA titer will be performed at an additional charge.
If the IFA pattern suggests phosphodiesterase 10A (PDE10A) antibody, then the PDE10A antibody IFA titer will be performed at an additional charge.
For more information see:
Autoimmune/Paraneoplastic Movement Disorder Evaluation Algorithm-Serum
Central Nervous System Demyelinating Disease Diagnostic Algorithm